annual meeting program - American Society of Clinical Oncology

Monday, June 7, 2010
Brd. 42B A phase II study of single-agent nab-paclitaxel as second-line therapy in
patients with metastatic urothelial carcinoma. (Abstract #TPS231)
S. S. Sridhar, C. M. Canil, S. D. Mukherjee, E. Winquist, C. Elser, A. Eisen, A.
Chung, Y. Ko
Brd. 42C First-line everolimus followed by second-line sunitinib versus the opposite
treatment sequence in patients with metastatic renal cell carcinoma (mRCC).
(Abstract #TPS232)
J. J. Knox, A. C. Kay, E. Schiff, N. Hollaender, N. Rouyrre, A. Ravaud, R. J. Motzer
Brd. 42D Open-label phase II trial of everolimus monotherapy in patients with
recurrent metastatic and/or unresectable renal cell carcinoma (RCC).
(Abstract #TPS233)
B. Tannir, S. Hardikar
Brd. 42E Open-label phase II trial of everolimus monotherapy in treatment-naive
patients with advanced papillary renal cell carcinoma. (Abstract #TPS234)
S. Caglio, K. Slimane, C. May, B. Escudier
Brd. 42F Axitinib with or without dose titration as first-line therapy for metastatic renal
cell carcinoma (mRCC). (Abstract #TPS235)
E. Jonasch, A. Bair, Y. Chen, B. I. Rini
Brd. 42G Treatment of refractory metastatic renal cell carcinoma (RCC) with
bevacizumab and RAD001. (Abstract #TPS236)
L. C. Harshman, A. McMillan, S. Srinivas
Brd. 42H A randomized double-blind cross-over patient preference study of pazopanib
versus sunitinib in treatment-naive locally advanced or metastatic renal cell
carcinoma (mRCC). (Abstract #TPS237)
B. J. Escudier, D. Cella, J. E. Gschwend, T. Powles, C. N. Sternberg, R. Hodge, M.
Lau, M. Neary, F. Mehmud, T. Eisen
Brd. 43A Everolimus with bevacizumab versus interferon alfa-2a plus bevacizumab as
first-line therapy in patients with metastatic clear cell renal cell carcinoma.
(Abstract #TPS238)
A. Ravaud, E. Bajetta, A. C. Kay, D. Pelov, N. Hollaender, N. Rouyrre, J. A.
Thompson
Brd. 43B Targeting epidermal growth factor receptor (EGFR) in urothelial cancer (UC):
A phase II randomized trial of cisplatin (C) with gemcitabine (G) with or
without cetuximab. (Abstract #TPS239)
A. S. Alva, N. Agarwal, A. O. Siefker-Radtke, B. J. Roth, D. C. Smith, S. Daignault,
S. Srinivas, D. A. Bradley, M. Hussain
Brd. 43C A phase II trial of docetaxel, cisplatin, and 5-fluorouracil (TPF) in locally
advanced and metastatic carcinoma of the penis (CRUK/09/001). (Abstract
#TPS240)
A. K. Bahl, S. Nicholson, J. Barber, E. Hall
Brd. 43D A randomized, double-blind, placebo-controlled phase II study of
testosterone replacement in men with asymptomatic castrate-resistant
prostate cancer (PC). (Abstract #TPS241)
R. Z. Szmulewitz, E. M. Posadas, B. Manchen, W. M. Stadler
Brd. 43E Anti-insulin-like growth factor-1 receptor (IGF-IR) monoclonal antibody
cixutumumab plus mammalian target of rapamycin (mTOR) inhibitor
temsirolimus in metastatic castration-resistant prostate cancer (CRPC).
(Abstract #TPS242)
D. E. Rathkopf, D. C. Danila, J. J. Chudow, M. J. Morris, S. F. Slovin, S. Fine, J. J.
Fox, S. M. Larson, N. Rosen, H. I. Scher
Brd. 43F Phase I/II study of sorafenib concurrent with androgen deprivation and
radiotherapy in treatment of intermediate- and high-risk localized prostate
cancer. (Abstract #TPS243)
S. Talwar, S. M. Cohen, N. A. Romas, R. D. Ennis
325
MONDAY